192 results
Page 6 of 10
8-K
zenu0kg zy2w
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.1
ba4i n5xfs2j308ycijl
8 Mar 22
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
7:04am
424B5
caa qi6w29
9 Feb 22
Prospectus supplement for primary offering
4:08pm
8-K
z5g93qonkfnal
5 Jan 22
Regulation FD Disclosure
7:01am
8-K
3hw28kc6ugl 42
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am
8-K
EX-99.1
yczq9uwe3
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am
8-K
EX-99.1
vxluv95xmvv75iwbflg3
4 Nov 21
Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights
7:01am
8-K
9qe9uelv8km 131m4gu
9 Sep 21
Regulation FD Disclosure
7:00am
8-K
EX-99.1
qdpqc8 h1x
5 Aug 21
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
8:30am
8-K
kk4 y2dmd37u63
24 Jun 21
Other Events
8:31am
8-K
EX-99.1
y2w8mdbtjiu21ate
10 May 21
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
8:30am
8-K
da4np95xe0nbdb2m6hq
22 Mar 21
Entry into a Material Definitive Agreement
8:30am